These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 38789373)

  • 1. Hybrid immunity after BNT162b2 Covid-19 vaccine administration in children aged 5 to 11 years.
    Tsampalieros A; Zemek R; Barrowman N; Langlois MA; Arnold C; McGahern C; Plint AC; Pham-Huy A; Bhatt M
    Vaccine; 2024 Aug; 42(20):125981. PubMed ID: 38789373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
    Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y
    Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.
    Sauré D; O'Ryan M; Torres JP; Zuniga M; Santelices E; Basso LJ
    Lancet Infect Dis; 2022 Jan; 22(1):56-63. PubMed ID: 34509185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A single mRNA vaccine dose in COVID-19 patients boosts neutralizing antibodies against SARS-CoV-2 and variants of concern.
    van Gils MJ; van Willigen HDG; Wynberg E; Han AX; van der Straten K; Burger JA; Poniman M; Oomen M; Tejjani K; Bouhuijs JH; Verveen A; Lebbink R; Dijkstra M; Appelman B; Lavell AHA; Caniels TG; Bontjer I; van Vught LA; Vlaar APJ; Sikkens JJ; Bomers MK; Russell CA; Kootstra NA; Sanders RW; Prins M; de Bree GJ; de Jong MD;
    Cell Rep Med; 2022 Jan; 3(1):100486. PubMed ID: 35103254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diversified humoral immunity and impacts of booster vaccines: SARS-CoV-2 antibody profile and Omicron BA.2 neutralization before and after first or second boosters.
    Zhang XS; Windau A; Meyers J; Yang X; Dong F
    Microbiol Spectr; 2024 Oct; 12(10):e0060524. PubMed ID: 39162540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.
    Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR
    Front Immunol; 2022; 13():827306. PubMed ID: 35173736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the SARS-CoV-2 Antibody Response to the BNT162b2 Vaccine in Patients Undergoing Hemodialysis.
    Yau K; Abe KT; Naimark D; Oliver MJ; Perl J; Leis JA; Bolotin S; Tran V; Mullin SI; Shadowitz E; Gonzalez A; Sukovic T; Garnham-Takaoka J; de Launay KQ; Takaoka A; Straus SE; McGeer AJ; Chan CT; Colwill K; Gingras AC; Hladunewich MA
    JAMA Netw Open; 2021 Sep; 4(9):e2123622. PubMed ID: 34473256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Humoral Immune Response after SARS-CoV-2 Vaccination Using Two Binding Antibody Assays and a Neutralizing Antibody Assay.
    Nam M; Seo JD; Moon HW; Kim H; Hur M; Yun YM
    Microbiol Spectr; 2021 Dec; 9(3):e0120221. PubMed ID: 34817223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and evolution of anti-SARS-CoV-2 spike protein titers after three doses of COVID-19 vaccination in people with HIV.
    Liu WD; Lin MS; Sun HY; Shih MC; Chuang YC; Huang YS; Lin KY; Li GC; Wu PY; Chen LY; Liu WC; Su YC; He PC; Chen YT; Lin CY; Cheng YC; Yao Y; Yeh YC; Liu CC; Pan MY; Luo YZ; Chang HY; Wang JT; Sheng WH; Hsieh SM; Chang SY; Hung CC
    J Microbiol Immunol Infect; 2024 Aug; 57(4):554-563. PubMed ID: 38429206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of the third dose of BNT162b2 vaccine on quantitative SARS-CoV-2 spike 1-2 IgG antibody titers in healthcare personnel.
    Romero-Ibarguengoitia ME; Rivera-Salinas D; Hernández-Ruíz YG; Armendariz-Vázquez AG; González-Cantú A; Barco-Flores IA; González-Facio R; Montelongo-Cruz LP; Del Rio-Parra GF; Garza-Herrera MR; Leal-Meléndez JA; Sanz-Sánchez MÁ
    PLoS One; 2022; 17(3):e0263942. PubMed ID: 35235587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Humoral immune response against SARS-CoV-2 after adapted COVID-19 vaccine schedules in healthy adults: The IMCOVAS randomized clinical trial.
    Steenackers K; Hanning N; Bruckers L; Desombere I; Marchant A; Ariën KK; Georges D; Soentjens P; D'Onofrio V; Hites M; Berens-Riha N; De Coster I; Damme PV
    Vaccine; 2024 Nov; 42(25):126117. PubMed ID: 39019657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Seroresponse to SARS-CoV-2 Vaccines among Maintenance Dialysis Patients over 6 Months.
    Hsu CM; Weiner DE; Manley HJ; Aweh GN; Ladik V; Frament J; Miskulin D; Argyropoulos C; Abreo K; Chin A; Gladish R; Salman L; Johnson D; Lacson EK
    Clin J Am Soc Nephrol; 2022 Mar; 17(3):403-413. PubMed ID: 35144972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levels and functionality of Pacific Islanders' hybrid humoral immune response to BNT162b2 vaccination and delta/omicron infection: A cohort study in New Caledonia.
    Inizan C; Courtot A; Sturmach C; Griffon AF; Biron A; Bruel T; Enouf V; Demaneuf T; Munier S; Schwartz O; Gourinat AC; Médevielle G; Jouan M; van der Werf S; Madec Y; Albert-Dunais V; Dupont-Rouzeyrol M
    PLoS Med; 2024 Sep; 21(9):e1004397. PubMed ID: 39325828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.
    Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD;
    Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of a Third Dose of BNT162b2 Vaccine With Incidence of SARS-CoV-2 Infection Among Health Care Workers in Israel.
    Spitzer A; Angel Y; Marudi O; Zeltser D; Saiag E; Goldshmidt H; Goldiner I; Stark M; Halutz O; Gamzu R; Slobodkin M; Amrami N; Feigin E; Elbaz M; Furman M; Bronstein Y; Chikly A; Eshkol A; Furer V; Mayer T; Meijer S; Melloul A; Mizrahi M; Yakubovsky M; Rosenberg D; Safir A; Spitzer L; Taleb E; Elkayam O; Silberman A; Eviatar T; Elalouf O; Levinson T; Pozyuchenko K; Itzhaki-Alfia A; Sprecher E; Ben-Ami R; Henig O
    JAMA; 2022 Jan; 327(4):341-349. PubMed ID: 35006256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First SARS-CoV-2 Omicron infection as an effective immune booster among mRNA vaccinated individuals: final results from the first phase of the PRIBIVAC randomised clinical trial.
    Poh XY; Lee IR; Tan CW; Chavatte JM; Fong SW; Goh YS; Rouers A; Wong N; Torres-Ruesta A; Mah SYY; Yeoh AYY; Gandhi M; Rahman N; Chin YQ; Lim JJ; Yoong TJK; Rao S; Chia PY; Ong SWX; Lee TH; Sadarangani SP; Lin RJH; Lim DRX; Chia W; Renia L; Ren EC; Lin RTP; Lye DC; Wang LF; Ng LFP; Young BE
    EBioMedicine; 2024 Sep; 107():105275. PubMed ID: 39137572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study.
    Angyal A; Longet S; Moore SC; Payne RP; Harding A; Tipton T; Rongkard P; Ali M; Hering LM; Meardon N; Austin J; Brown R; Skelly D; Gillson N; Dobson SL; Cross A; Sandhar G; Kilby JA; Tyerman JK; Nicols AR; Spegarova JS; Mehta H; Hornsby H; Whitham R; Conlon CP; Jeffery K; Goulder P; Frater J; Dold C; Pace M; Ogbe A; Brown H; Ansari MA; Adland E; Brown A; Chand M; Shields A; Matthews PC; Hopkins S; Hall V; James W; Rowland-Jones SL; Klenerman P; Dunachie S; Richter A; Duncan CJA; Barnes E; Carroll M; Turtle L; de Silva TI;
    Lancet Microbe; 2022 Jan; 3(1):e21-e31. PubMed ID: 34778853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Follow-Up and Comparative Assessment of SARS-CoV-2 IgA, IgG, Neutralizing, and Total Antibody Responses After BNT162b2 or mRNA-1273 Heterologous Booster Vaccination.
    Younes S; Nicolai E; Pieri M; Bernardini S; Daas HI; Al-Sadeq DW; Younes N; Shurrab FM; Nizamuddin PB; Humaira F; Al-Dewik N; Yassine HM; Abu-Raddad LJ; Ismail A; Nasrallah GK
    Influenza Other Respir Viruses; 2024 May; 18(5):e13290. PubMed ID: 38706402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity of Monovalent mRNA-1273 and BNT162b2 Vaccines in Children <5 Years of Age.
    Dalapati T; Williams CA; Giorgi EE; Hurst JH; Herbek S; Chen JL; Kosman C; Rotta AT; Turner NA; Pulido N; Aquino JN; Pfeiffer TS; Rodriguez J; Fouda GG; Permar SR; Kelly MS
    Pediatrics; 2024 Jun; 153(6):. PubMed ID: 38548700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History.
    Tarkowski M; de Jager W; Schiuma M; Covizzi A; Lai A; Gabrieli A; Corbellino M; Bergna A; Ventura CD; Galli M; Riva A; Antinori S
    Front Immunol; 2021; 12():793191. PubMed ID: 34975897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.